Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2012 | Research

Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis

Authors: Yuan Xu, Qin Li, Xiao-Yu Li, Qiu-Ya Yang, Wei-Wei Xu, Gao-Lin Liu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2012

Abstract

Background

Antiangiogenic therapy is one of the most significant advances in anticancer treatment. The benefits of antiangiogenic therapies of late-stage cancers have been investigated but are still too limited.

Methods

We used an ovarian cancer model to test the effect of short-term bevacizumab treatment on metastasis as measured by bioluminescence. Western blotting and CD34-PAS dual staining were performed to assess hypoxia-inducible transcription factor-1α (HIF-1α) expression and vasculogenic mimicry(VM) formation. Cell viability was examined by a CCK8 assay.

Results

Bevacizumab demonstrated antitumor effects in models of ovarian cancer, but also accelerated metastasis together, with marked hypoxia and VM formation in mice receiving short-term therapy. Bevacizumab treatment did not affect SKOV3 cell viability and the amount of VM in three-dimensional culture.

Conclusion

These results suggest that antiangiogenic therapy may potentially influence the progression of metastatic disease, which has been linked to the hypoxic response and VM formation.

Available only for authorised users

Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971, 285: 1182-1186. 10.1056/NEJM197111182852108.CrossRefPubMed

Samaranayake H, Määttä AM, Pikkarainen J, Ylä-Herttuala S: Future prospects and challenges of antiangiogenic cancer gene therapy. Hum Gene Ther. 2010, 21 (4): 381-96. 10.1089/hum.2010.017.CrossRefPubMed

Kerbel RS: Tumor angiogenesis. N Engl J Med. 2008, 358: 2039-2049. 10.1056/NEJMra0706596.PubMedCentralCrossRefPubMed

Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005, 307: 58-62. 10.1126/science.1104819.CrossRefPubMed

Qu B, Guo L, Ma J, Lv Y: Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system. Med Hypotheses. 2010, 74 (2): 360-361. 10.1016/j.mehy.2009.08.020.CrossRefPubMed

Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005, 8: 299-309. 10.1016/j.ccr.2005.09.005.CrossRefPubMed

Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA: Anti- VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000, 2: 306-314. 10.1038/sj.neo.7900102.PubMedCentralCrossRefPubMed

Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001, 61: 6624-6628.PubMed

Cong R, Sun Q, Yang L, Gu H, Zeng Y, Wang B: Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells. J Exp Clin Cancer Res. 2009, 28: 124-10.1186/1756-9966-28-124.PubMedCentralCrossRefPubMed

10.

Miyamoto T, Min W, Lillehoj HS: Lymphocyte proliferation response during Eimeria tenella infection assessed by a new, reliable, nonradioactive colorimetric assay. Avian Dis. 2002, 46: 10-16. 10.1637/0005-2086(2002)046[0010:LPRDET]2.0.CO;2.CrossRefPubMed

11.

Pölcher M, Eckhardt M, Coch C, Wolfgarten M, Kübler K, Hartmann G, Kuhn W, Rudlowski C: Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol. 2010, DOI 10. 1007/s00280-010-1276-2

12.

Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009, 15: 232-239. 10.1016/j.ccr.2009.01.021.PubMedCentralCrossRefPubMed

13.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009, 15: 220-231. 10.1016/j.ccr.2009.01.027.PubMedCentralCrossRefPubMed

14.

Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008, 13: 206-220. 10.1016/j.ccr.2008.01.034.PubMedCentralCrossRefPubMed

15.

Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003, 3: 347-361. 10.1016/S1535-6108(03)00085-0.CrossRefPubMed

16.

Semenza GL: Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets. 2006, 10: 267-280. 10.1517/14728222.10.2.267.CrossRefPubMed

17.

Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, Hendrix MJ: Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol. 2004, 190: 899-909. 10.1016/j.ajog.2004.02.011.CrossRefPubMed

18.

Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Cohen MB, Lubaroff DM, Hendrix MJ: Prostatic tumor cell plasticity involves cooperative interaction of distinct phenotypic subpopulations: role in vasculogenic mimicry. The Prostate. 2002, 50: 189-201. 10.1002/pros.10048.CrossRefPubMed

19.

Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer. 2002, 99: 821-828. 10.1002/ijc.10423.CrossRefPubMed

20.

van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, Delattre O, Maxwell PH, Hendrix MJ, Griffioen AW: Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 2005, 65: 11520-11528. 10.1158/0008-5472.CAN-05-2468.CrossRefPubMed

21.

Van Rompaey L, Holland E, Grosveld G: TEL induces aggregation in transformed cells and induces tube formation in NIH3T3-UCLA cells. Biochem Biophys Res Commun. 2002, 291: 820-828. 10.1006/bbrc.2002.6513.CrossRefPubMed

22.

Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, Cesario A, Granone P, Nicholson AG, Goldstraw P, Ratcliffe C, Tetlow M, Leigh I, Harris AL, Gatter KC, Pezzella F: Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer. 2002, 86: 244-249. 10.1038/sj.bjc.6600015.PubMedCentralCrossRefPubMed

23.

Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999, 155: 739-752. 10.1016/S0002-9440(10)65173-5.PubMedCentralCrossRefPubMed

24.

Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, Gruman LM: The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993, 100: 1389-1398.CrossRefPubMed

25.

Sun B, Zhang S, Zhao X, Zhang W, Hao X: Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol. 2004, 25: 1609-1614.PubMed

26.

Yao LQ, Feng YJ, Ding JX, Xu CJ, Jin HY, Yin LH: Primary study of vasculogenic mimicry induced by hypoxia in epithelial ovarian carcinoma. Zhoughua Fu Chan Ke Za Zhi (Chinese). 2005, 40: 662-665.

27.

Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Molecular plasticity of human melanoma cells. Oncogene. 2003, 22: 3070-3075. 10.1038/sj.onc.1206447.CrossRefPubMed

28.

Zhang S, Zhang D, Sun B: Vasculogenic mimicry: current status and future prospects. Cancer Lett. 2007, 254: 157-164. 10.1016/j.canlet.2006.12.036.CrossRefPubMed

29.

Yao LQ, Feng YJ, Ding JX, Jing HM, Xu CJ, Chen SF, Su M, Yin LH: Characteristics and differentiated mechanism of vascular endothelial cells-like derived from epithelial ovarian cancer cells induced by hypoxia. Int J Oncol. 2007, 30: 1069-1075.PubMed

30.

Hendrix MJ, Seftor RE, Seftor EA, Gruman LM, Lee LM, Nickoloff BJ, Miele L, Sheriff DD, Schatteman GC: Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res. 2002, 62: 665-668.PubMed

31.

Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X: Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett. 2007, 249: 188-197. 10.1016/j.canlet.2006.08.016.CrossRefPubMed

Title: Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis
Authors: Yuan Xu
Qin Li
Xiao-Yu Li
Qiu-Ya Yang
Wei-Wei Xu
Gao-Lin Liu
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2012
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-31-16

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin

Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation

Enhancement of radiation response with bevacizumab

Are there candidates for high-dose chemotherapy in ovarian carcinoma?

Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer

Tumorigenesis role and clinical significance of DJ-1, a negative regulator of PTEN, in supraglottic squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer